Compare PW & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | GOVX |
|---|---|---|
| Founded | 1967 | 2001 |
| Country | United States | United States |
| Employees | 2 | 19 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.8M |
| IPO Year | N/A | N/A |
| Metric | PW | GOVX |
|---|---|---|
| Price | $7.85 | $0.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 14.1K | ★ 198.4K |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.12 |
| 52 Week High | $12.92 | $4.40 |
| Indicator | PW | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 33.53 |
| Support Level | $0.71 | $0.64 |
| Resistance Level | $11.62 | $2.00 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 23.44 | 21.62 |
Power REIT is an internally-managed real estate investment trust that owns a portfolio of real estate assets related to transportation, energy infrastructure and Controlled Environment Agriculture in the United States. Its assets consisted of approximately 112 miles of railroad infrastructure and related real estate which is owned by its subsidiary, approximately 447 acres of fee simple land leased to a utility scale solar power generating project with an aggregate generating capacity of approximately 82 Megawatts and approximately 82 acres of land with approximately 357,000 square feet of CEA properties in the form of greenhouses. The company invested in greenhouses for state-licensed cannabis and food cultivation.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.